MedTrace

MedTrace is a Copenhagen-based biotech innovator, founded in 2018, focused on transforming perfusion imaging for cardiovascular disease. The company's core technology is an automated, on-site system for producing and infusing the PET tracer Oxygen-15 water, combined with its aQuant analytical software, to provide quantitative myocardial blood flow measurements. While the technology is recognized as a gold standard in research, MedTrace is navigating the regulatory path, with a Phase 3 trial ongoing in the US and a CE mark for its software in Europe, positioning it to address a significant unmet need in non-invasive cardiac diagnostics. The company is privately held and appears to be in a pre-revenue, late-clinical development stage.

Integrated point-of-care system for ¹⁵O-water PET imaging. Comprises the 'P3' automated hardware for on-site production/infusion of the ¹⁵O-water tracer and the 'aQuant' software for quantitative analysis of myocardial blood flow from PET scans.

MedTrace competes with established myocardial perfusion imaging modalities like SPECT and PET using tracers such as Rubidium-82 or Ammonia-13, which offer simpler logistics but potentially inferior quantitative accuracy. It also faces competition from advanced cardiac MRI techniques. Its key differentiator is providing gold-standard quantitative flow data, but it must overcome higher operational complexity.